CONTACT
|
PROVIDER PORTAL
|
PROVIDER SEARCH
|
REIMBURSEMENT
INDICATIONS
Musculoskeletal
SoftWave Wound Care
Wound Case Study
Mens Urological and Sexual Health
Womens Pelvic Health
ABOUT
SoftWave Technology
OrthoGold
UroGold
DermaGold 100®
Shockwave Therapy
ABOUT US
BOARD
Patents
Privacy Policy
News & Press Releases
FDA Clearances
Newsletters
Softwave Blog
FAQs
Events
RESEARCH
Pain/Sports Med/Regenerative Research Library
Urology Research Library
Podiatry Research Library
Wound/Burn Research Library
PATIENTS
BECOME A PROVIDER
DISTRIBUTORS
CONTACT US
Contact Us
PROVIDERS SEARCH
CONTACT
|
PROVIDER PORTAL
|
PROVIDER SEARCH
|
REIMBURSEMENT
INDICATIONS
Musculoskeletal
SoftWave Wound Care
Wound Case Study
Mens Urological and Sexual Health
Womens Pelvic Health
ABOUT
SoftWave Technology
OrthoGold
UroGold
DermaGold 100®
Shockwave Therapy
ABOUT US
BOARD
Patents
Privacy Policy
News & Press Releases
FDA Clearances
Newsletters
Softwave Blog
FAQs
Events
RESEARCH
Pain/Sports Med/Regenerative Research Library
Urology Research Library
Podiatry Research Library
Wound/Burn Research Library
PATIENTS
BECOME A PROVIDER
DISTRIBUTORS
CONTACT US
Contact Us
PROVIDERS SEARCH
Home
Protocols
Service/Troubleshooting
Marketing
ROI Calculator
Clinical Docs
FAQ
Refurbishments
Cart
Contact Us
Logout
The influence of comorbidities and etiologies on the success of extracorporeal shock wave therapy for chronic soft tissue wounds: midterm results.
SoftWave Literature
Wolff et al.
Ultrasound Med Biol. 2011 Jul;37(7):1111-9.
Click here to read more.
0
Shares
Prev
Next
Related Posts
Sticky Post
SoftWave TRT Lands Prestigious VA Contract Revolutionizing Pain and Wound Management for Veterans
News
Extracorporeal Shock Wave Therapy
Blog
Shockwave Therapy for Calcific Tendonitis
Blog
